98. 好酸球性消化管疾患 Eosinophilic gastrointestinal disease Clinical trials / Disease details


臨床試験数 : 172 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000082-16-DE
(EUCTR)
21/01/202129/07/2020A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusA randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis Active eosinophilic esophagitis
MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: ESO-101
Product Code: ESO-101
INN or Proposed INN: mometasone
Other descriptive name: MOMETASONE FUROATE
EsoCap AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Phase 2Spain;Netherlands;Germany;Switzerland
2EUCTR2020-000082-16-NL
(EUCTR)
29/10/202003/09/2020A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusA randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis Active eosinophilic esophagitis
MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: ESO-101
Product Code: ESO-101
INN or Proposed INN: mometasone
Other descriptive name: MOMETASONE FUROATE
EsoCap AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Phase 2Spain;Germany;Netherlands;Switzerland
3NCT02113267
(ClinicalTrials.gov)
April 201410/4/2014Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.Treatment of Eosinophilic Esophagitis With Mometason Furoat Aerosol: a Randomised, Placebo-controled Phase II Study for Evaluation of Treatment Effect on Group Level Including Symtom QuestionnairesEosinophilic EsophagitisDrug: Mometasone furoate;Drug: PlaceboMogens BoveVastra Gotaland RegionTerminated18 YearsN/AAll40Phase 2Sweden
4EUCTR2012-005842-39-SE
(EUCTR)
20/12/201305/11/2013Treatment of patients with eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II studyTreatment of eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II study for evaluation of treatment effect on group level including symtom questionnaires Eosinphilic Esophagitis;Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]Trade Name: NasonexNU-sjukvården, Norra Älvsborgs LänssjukhusNULLNot Recruiting Female: yes
Male: yes
60 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noSweden